The structural scaffold and binding mode of ST‐CY14 make it a promising lead compound for further development in breast cancer treatment, and will facilitate the further design and modification of inhibitors in the Nur77‐PPARγ interface. This evidence concerns the gene NR4A1 and breast cancer.